Overactive Bladder

Systematic review and meta-analysis on the association of metabolic syndrome in women with overactive bladder. January 10, 2025

Trends in Medicare Coverage of Overactive Bladder Medications in the United States. January 10, 2025

Complicated Overactive Bladder Management. January 10, 2025

Frailty, Specialized Care, and Sociodemographic Factors: Disparities in Oral Pharmacotherapy Class Utilization Among Medicare Part D Beneficiaries With Overactive Bladder in the United States January 3, 2025

The Association Between Anthropometric Indices and Overactive Bladder (OAB): A Cross-Sectional Study From the NHANES 2005-2018. January 3, 2025

Antibiotic therapy for treating overactive bladder is not supported by clinical evidence. January 3, 2025

A Systematic Review of the Prevalence of Overactive Bladder in Women with Non-Urinary Tract Endometriosis and the Effect of Endometriosis Surgery on Symptoms of Overactive Bladder. January 3, 2025

Risks of Dementia Associated With Anticholinergic Medication Compared to Beta-3 Agonist Among Older Patients With Overactive Bladder in Japan: The LIFE Study. January 3, 2025

Clinical Features and Current Pharmacotherapy of OAB in Practice: Ideal and Reality. December 29, 2024

Endocrine disruptors and bladder function: the role of phthalates in overactive bladder. December 29, 2024

Variation in Overactive Bladder Treatment Type by Social Determinants of Health. December 29, 2024

The relationship between increased regional body fat and overactive bladder: a population-based study. December 29, 2024

Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia December 23, 2024

Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial. December 22, 2024

Plain Language Summary of Publication: Does crushing vibegron 75 mg tablet affect its safety or the amount of vibegron in the body over time in healthy adults? December 15, 2024

Patient Persistence to OnabotulinumtoxinA Treatment for Overactive Bladder Using a Reduced Injection-Site Paradigm: A Retrospective Chart Review Study. December 15, 2024

Impact of body mass index on the efficacy of treatment modalities in women with refractory overactive bladder. December 8, 2024

Evaluating the Efficacy and Safety of Botulinum Toxin in Treating Overactive Bladder in the Elderly: A Meta-Analysis with Trial Sequential Analysis of Randomized Controlled Trials. December 8, 2024

Blood cadmium levels and overactive bladder in middle-aged and older adults in the United States: Insights from NHANES 2007-2020 data. December 1, 2024

Assessing the Work Productivity Impact of Overactive Bladder Syndrome Among Employees at a Brazilian Hospital. December 1, 2024

Page 1 of 123